ChromaDex Corporation (CDXC): Price and Financial Metrics

ChromaDex Corporation (CDXC): $1.45

0.02 (+1.40%)

POWR Rating

Component Grades








Add CDXC to Watchlist
Sign Up

Industry: Chemicals




#1 of 83

in industry

CDXC Price/Volume Stats

Current price $1.45 52-week high $2.24
Prev. close $1.43 52-week low $1.16
Day low $1.40 Volume 125,600
Day high $1.46 Avg. volume 126,761
50-day MA $1.55 Dividend yield N/A
200-day MA $1.61 Market Cap 108.80M

CDXC Stock Price Chart Interactive Chart >


  • Growth is the dimension where CDXC ranks best; there it ranks ahead of 94.65% of US stocks.
  • The strongest trend for CDXC is in Quality, which has been heading up over the past 177 days.
  • CDXC's current lowest rank is in the Momentum metric (where it is better than 12.19% of US stocks).

CDXC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CDXC is 2.98 -- better than 81.87% of US stocks.
  • Price to trailing twelve month operating cash flow for CDXC is currently 51.29, higher than 93.33% of US stocks with positive operating cash flow.
  • For CDXC, its debt to operating expenses ratio is greater than that reported by just 12.17% of US equities we're observing.
  • Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are IRMD, PMD, SPWR, LPRO, and STIM.
  • Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to

CDXC Valuation Summary

  • In comparison to the median Healthcare stock, CDXC's price/earnings ratio is 159.18% lower, now standing at -15.8.
  • CDXC's price/sales ratio has moved down 0.2 over the prior 175 months.

Below are key valuation metrics over time for CDXC.

Stock Date P/S P/B P/E EV/EBIT
CDXC 2023-09-22 1.3 3.8 -15.8 -12.0
CDXC 2023-09-21 1.3 3.8 -16.1 -12.2
CDXC 2023-09-20 1.3 3.8 -15.9 -12.1
CDXC 2023-09-19 1.3 3.9 -16.4 -12.5
CDXC 2023-09-18 1.3 3.9 -16.2 -12.3
CDXC 2023-09-15 1.4 4.1 -17.0 -13.1

CDXC Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -28.42%.
  • Its 2 year revenue growth rate is now at 38.42%.
  • Its year over year cash and equivalents growth rate is now at -53.03%.
CDXC's revenue has moved up $6,806,000 over the prior 15 months.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 68.813 -19.714 -20.447
2022-06-30 69.058 -21.893 -28.318
2022-03-31 70.025 -25.956 -27.487
2021-12-31 67.449 -24.163 -27.128
2021-09-30 65.135 -19.197 -27.9
2021-06-30 62.007 -17.123 -23.259

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
  • CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
  • MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.115 0.615 -3.082
2021-06-30 1.178 0.612 -2.751
2021-03-31 1.276 0.607 -3.100
2020-12-31 1.545 0.595 -2.616
2020-09-30 1.466 0.586 -2.883
2020-06-30 1.361 0.577 -2.841

CDXC Price Target

For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.80 Average Broker Recommendation 1.3 (Strong Buy)

ChromaDex Corporation (CDXC) Company Bio

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.

CDXC Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream

Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

Insider Stock Buying Reaches US$1.3m On ChromaDex

Multiple insiders secured a larger position in ChromaDex Corporation ( NASDAQ:CDXC ) shares over the last 12 months...

Yahoo | September 3, 2023

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

LOS ANGELES, August 24, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares findings from a preclinical study, as reported in the peer-reviewed journal International Journal of Molecular Sciences by a team of scientists led by Dr. Yue Yang, Assistant Professor of Research in Pharmacology at Weill Cornell Medicine in New York.

Yahoo | August 24, 2023

Analysts Expect Breakeven For ChromaDex Corporation (NASDAQ:CDXC) Before Long

With the business potentially at an important milestone, we thought we'd take a closer look at ChromaDex Corporation's...

Yahoo | August 12, 2023

Q2 2023 Chromadex Corp Earnings Call

Q2 2023 Chromadex Corp Earnings Call

Yahoo | August 10, 2023

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2023

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -5.84%
3-mo -7.64%
6-mo -5.23%
1-year 19.83%
3-year -64.02%
5-year -66.20%
YTD -13.69%
2022 -55.08%
2021 -22.08%
2020 11.37%
2019 25.66%
2018 -41.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!